Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 1Plasma cell 1Lymphoid 1Gynecologic 1

Conditions

Cholangiocarcinoma 2Adenocarcinoma Of Esophagus 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 114Bevacizumab 111Specimen Handling 101Leucovorin 101Capecitabine 87Magnetic Resonance Spectroscopy 81pembrolizumab 78Cisplatin 74Nivolumab 70Irinotecan 68Cetuximab 58130-nm albumin-bound paclitaxel 58durvalumab 57Paclitaxel 57Biopsy 55atezolizumab 42Radiotherapy 40Albumin-Bound Paclitaxel 36Taxes 35Folfox protocol 34Carboplatin 34Drug Therapy 28lenvatinib 27sintilimab 26dehydroftorafur 26Radiation 26Cyclophosphamide 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
futibatinib × Gastrointestinal × 90 days × Clear all
NCT05727176 2026-05-28

FOENIX-CCA4

Taiho Oncology, Inc.

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT06506955 2026-05-28

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡